Listen to Mike Mangano, president and CEO discussing the strides ABK Biomedical is taking to advance the treatment of liver cancer
Latest News
October 24th 2023
ABK Biomedical Announces First Patient Treated in its Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Go to the Press Release»»
May 30th 2023
ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Go to the Press Release»»
December 6th 2022
ABK Biomedical Raises USD 30M in Series C Funding
Go to the Press Release»»
September 12th 2022
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
Go to the Press Release»»
September 12th 2022
ABK Biomedical announces the appointment of Dr. Aravind Arepally as Chief Medical Officer effective, September 12th 2022
Meet Our New CMO»»
Meet Our CMO
Dr. Aravind Arepally was appointed to a newly created, full-time position of Chief Medical Officer on September 12th, 2022.
Aravind joined ABK with extensive clinical experience in Interventional Oncology, Y90 procedures, and the medical device industry. Aravind obtained his medical degree and completed his radiology residency at Emory University in Atlanta. After finishing his fellowship at Johns Hopkins Medical Institutes, he joined the faculty, becoming an Associate Professor of Radiology and Surgery. Aravind eventually moved back to Atlanta as a practicing physician in private practice, becoming the Chair of Radiology, Section Chief of IR, and a member of the Board of Directors at Radiology Associates of Atlanta at Piedmont Hospital. He is also currently an Adjunct Professor of Radiology at Vanderbilt University School of Medicine.
In the area of medical technology development, Aravind co-founded Surefire Medical in 2010 where he was Chief Scientific Officer and spent 10 years guiding pre-clinical research, global clinical trials/strategy, and FDA interactions. Surefire (now TriSalus Life Sciences) is now commercially available in US, Europe, Asia, and South America. Additional prior industry experience includes time as a Visiting Clinical Scientist with Siemen’s Healthcare focusing on molecular imaging and image guided therapies. Most recently, Aravind left full-time clinical practice and was appointed Senior Director of R&D for Varian, Siemens Healthineers.
Aravind has received numerous NIH Grants and completed several human clinical trials in the areas of Imaging, Medical Devices, and embolotherapies. He is an author on over 150 publications, numerous medical textbooks, and has been part of faculty and lectures at over 100 conferences in his career. He has extensive teaching and mentoring experience and has consulted for many companies in the Interventional Radiology and Oncology space. He is a widely respected Key Opinion Leader in Interventional Medicine and has performed over 500 Yttrium 90 procedures in his career. His unique combination of industry, start-up, imaging, radiology, and oncology experience make him uniquely suited as the Chief Medical Officer at ABK Biomedical Inc.

Aravind Arepally, MD., Chief Medical Officer
Company News & Press Releases
ABK Biomedical Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Halifax, Nova Scotia. May 30th, 2023. ABK Biomedical an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies…
Read the Press Release»»
ABK Biomedical Raises USD 30M in Series C Financing
Halifax, Nova Scotia. December 6th 2022. ABK Biomedical an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies…
Read the Press Release»»
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
Halifax, Nova Scotia. September 12th 2022. ABK Biomedical, an innovative medical device company dedicated to the research…
Read the Press Release»»
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
Halifax, Nova Scotia. April 19th, 2022. ABK Biomedical, Inc, an innovative, clinical-stage medical device company dedicated to the research…
Read the Press Release»»
Our Products
Eye90 microspheres®
A novel technology for Y90 radioembolization made with a proprietary, imageable glass composition for in-procedure visualization.
Easi-Vue™ embolic microspheres
Imageable bland embolization product allowing direct visualization at the target site. FDA 510(k) clearance for the embolization of arteriovenous malformations and hypervascular tumors.
Leadership Team

Michael Mangano
> an accomplished global executive leader with over 25 years’ experience in the medical device industry.

Gary Donofrio
> extensive marketing and commercialization experience with over 25 years in the medical device field.

Mike Tyson
> over 35 years’ experience in public accounting and leadership positions.

Aravind Arepally
> Chief Medical Officer and practicing Interventional Radiologist with extensive industry and academic experience.

David Dobrowski
> an accomplished Life Sciences Executive and Enterprise Leader with over 25 years of pharmaceutical and medical device development experience.

Mark Gregoire
> an accomplished professional mechanical engineer with extensive experience in the nuclear medical products sector.

Anthony Headley
> an accomplished medical device executive with 25 years experience leading and building engineering, manufacturing, and R&D organizations.
The ABK Biomedical Team
We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.
ABK Biomedical is an equal opportunity employer offering competitive compensation packages.
ABK's Business Partners
ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.
Research Partners
Development Partners
Corporate Offices
Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada
T. 902.442.4009
Orange County Office
555 Corporate Drive
Suite 105
Ladera Ranch, CA, 92694
USA
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. Eye90 microspheres® is considered an investigational product and is NOT FDA-approved for use.
Copyright 2022 - All International Rights Reserved